Glycine in dogs: the evidence
What the aging-research databases and the canine literature hold for Glycine (names searched: Glycine). Compiled from DrugAge, the canine aging corpus and FDA CVM FOI summaries; nothing here is inferred.
Lifespan experiments in other species (DrugAge)
8 experiments recorded, by species: Caenorhabditis elegans 6, Mus musculus 2.
NIA Interventions Testing Program rows
| Species | Strain | Dose | Age at start | Duration | Sex | Mean lifespan Δ% | Mean sig. | Max lifespan Δ% | Max sig. | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Mus musculus | UM-HET3 | 80000 ppm food | 9 months | until death | Female | 4 | S | 2 | NS | PMID 30916479 |
| Mus musculus | UM-HET3 | 80000 ppm food | 9 months | until death | Male | 6 | S | 5 | S | PMID 30916479 |
Other DrugAge rows (sample)
| Species | Strain | Dose | Age at start | Duration | Sex | Mean lifespan Δ% | Mean sig. | Max lifespan Δ% | Max sig. | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | N2 | 10 mM | Unknown | -4 | NS | NA | PMID 25643626 | |||
| Caenorhabditis elegans | N2 | 1 mM | Unknown | 10 | S | NA | PMID 25643626 | |||
| Caenorhabditis elegans | N2 | 5 mM | Unknown | 3 | NS | NA | PMID 25643626 | |||
| Caenorhabditis elegans | N2 | 5 µM | Unknown | 7.85 | S | NA | PMID 30845140 | |||
| Caenorhabditis elegans | N2 | 500 µM | Unknown | 19.54 | S | NA | PMID 30845140 | |||
| Caenorhabditis elegans | N2 | 50 µM | Unknown | 17.6 | S | NA | PMID 30845140 |
Lifespan experiments in dogs (DrugAge)
DrugAge records no dog lifespan experiment for this compound.
Dog-equivalent doses (allometric starting points, not recommendations)
Method: FDA 2005 Km body-surface-area conversion; starting-point heuristic only.
No mg/kg dose in DrugAge to translate (doses reported as ppm of diet or a concentration).
Canine aging literature (Europe PMC corpus)
12 corpus records mention this compound.
Records matching randomized or placebo-controlled trial vocabulary
- Comparison of the precursor, amino acid oxidation, and end-product methods for the evaluation of protein turnover in senior dogs. (PloS one, 2024). PMID 38900837
…The present study compared the methods of precursor (13C-Leucine), end-products (15N-Glycine), and amino acid oxidation (13C-Phenylalanine) to determine the whole…
Top hits in the core tier
- Inhibition of elastin degradation alleviates joint degeneration in aging mice, dogs, and human models. (Proceedings of the National Academy of Sciences of the United States of America, 2026). PMID 42418481
- The role of oxygen free radicals in organ preservation. (Klinische Wochenschrift, 1991). PMID 1798282
- Bilirubin metabolism in canine hepatobiliary and haemolytic disease. (The veterinary quarterly, 1987). PMID 3672859
- Effects of dietary protein on whole-body protein turnover and endocrine function in young-adult and aging dogs. (Journal of animal science, 2001). PMID 11811469
- IDENTIFICATION OF A MULTIDIMENSIONAL FOOD–AMINO ACID–DEFINED CIRCADIAN LONGEVITY ZONE (Innovation in aging, 2017).
- Metabolic phenotype modulation by caloric restriction in a lifelong dog study. (Journal of proteome research, 2013). PMID 23713866
- The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. (Fitoterapia, 2012). PMID 22391022
FDA CVM FOI summaries for dog products
No FDA FOI summary for a dog product contains this ingredient (it is not a marketed veterinary product).
Evidence gaps reported by the dossier tool
- DrugAge has no dog lifespan experiment for this compound.
- No mg/kg animal dose in DrugAge to translate (doses reported as ppm or % of diet).
- No FDA FOI summary for a dog product containing this ingredient.
Reproduce: intervention_dossier(compound="Glycine") in dog-geroscience-mcp.